These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33038327)

  • 1. Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity.
    Zeng Q; Huang G; Li YZ; Xu Y
    Mol Ther; 2020 Nov; 28(11):2314-2315. PubMed ID: 33038327
    [No Abstract]   [Full Text] [Related]  

  • 2. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.
    Zedan HT; Nasrallah GK
    EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435
    [No Abstract]   [Full Text] [Related]  

  • 3. Cross-reactive antibody immunity against SARS-CoV-2 in children and adults.
    Fraley E; LeMaster C; Banerjee D; Khanal S; Selvarangan R; Bradley T
    Cell Mol Immunol; 2021 Jul; 18(7):1826-1828. PubMed ID: 34059791
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological imprinting of the antibody response in COVID-19 patients.
    Aydillo T; Rombauts A; Stadlbauer D; Aslam S; Abelenda-Alonso G; Escalera A; Amanat F; Jiang K; Krammer F; Carratala J; García-Sastre A
    Nat Commun; 2021 Jun; 12(1):3781. PubMed ID: 34145263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
    Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactive adaptive immunity against coronaviruses in young children.
    Nat Immunol; 2022 Jan; 23(1):11-12. PubMed ID: 34937929
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
    Mveang Nzoghe A; Essone PN; Leboueny M; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Avome Houechenou RM; Agnandji ST; Djoba Siawaya JF
    Immun Inflamm Dis; 2021 Mar; 9(1):128-133. PubMed ID: 33320447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive detection of anti-spike antibodies enables improved understanding of SARS-CoV-2 pathogenesis.
    Milling S
    Immunology; 2021 Sep; 164(1):1-2. PubMed ID: 34382228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
    Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
    Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity.
    Lehmann AA; Kirchenbaum GA; Zhang T; Reche PA; Lehmann PV
    Front Immunol; 2021; 12():635942. PubMed ID: 34127926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19.
    Meinberger D; Koch M; Roth A; Hermes G; Stemler J; Cornely OA; Streichert T; Klatt AR
    Sci Rep; 2021 Apr; 11(1):8920. PubMed ID: 33903660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.
    Lin CY; Wolf J; Brice DC; Sun Y; Locke M; Cherry S; Castellaw AH; Wehenkel M; Crawford JC; Zarnitsyna VI; Duque D; Allison KJ; Allen EK; Brown SA; Mandarano AH; Estepp JH; ; Taylor C; Molina-Paris C; Schultz-Cherry S; Tang L; Thomas PG; McGargill MA
    Cell Host Microbe; 2022 Jan; 30(1):83-96.e4. PubMed ID: 34965382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
    Reche PA
    Front Immunol; 2020; 11():586984. PubMed ID: 33178220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts.
    Kundu R; Narean JS; Wang L; Fenn J; Pillay T; Fernandez ND; Conibear E; Koycheva A; Davies M; Tolosa-Wright M; Hakki S; Varro R; McDermott E; Hammett S; Cutajar J; Thwaites RS; Parker E; Rosadas C; McClure M; Tedder R; Taylor GP; Dunning J; Lalvani A
    Nat Commun; 2022 Jan; 13(1):80. PubMed ID: 35013199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
    Ahn TS; Han B; Krogstad P; Bun C; Kohn LA; Garcia-Lloret MI; Damoiseaux R; Butte MJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):876-877. PubMed ID: 33358557
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Béguelin A
    Rev Med Suisse; 2021 Jan; 17(723):234. PubMed ID: 33507668
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
    Dalakas MC; Bitzogli K; Alexopoulos H
    Front Immunol; 2021; 12():627285. PubMed ID: 33679770
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
    Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T
    Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
    Jackson-Thompson BM; Goguet E; Laing ED; Olsen CH; Pollett S; Hollis-Perry KM; Maiolatesi SE; Illinik L; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Davies J; Ortega O; Parmelee E; Lindrose AR; Moser M; Graydon E; Letizia AG; Duplessis CA; Ganesan A; Pratt KP; Malloy AM; Scott DW; Anderson SK; Snow AL; Dalgard CL; Powers JH; Tribble D; Burgess TH; Broder CC; Mitre E
    BMC Infect Dis; 2021 Jun; 21(1):544. PubMed ID: 34107889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.